Home / Investors

Neurostimulation:
seize a growing opportunity

Neurinnov:
A PIONEER IN NEUROSTIMULATION WITH STRONG FOUNDATIONS

The rise in neurostimulation therapies and an aging population are key drivers of growth in the neurostimulation market. Neurinnov is uniquely positioned to capitalise on these opportunities with its ground-breaking implantable functional electrical stimulation solutions

Addressing a critical unmet need: Patients with high tetraplegia face a 50% reduction in life expectancy and annual care costs of up to $230,000. No cure exists, and lifelong 24/7 support is required.
15+ years of R&D driving a highly differentiated platform: ASIC-based selective neurostimulation platform enabling precise muscle activation with only two neural electrodes. Quick, easy setup via connected hardware, advanced algorithms, and an intuitive interface. Compact, ergonomic, and user-friendly.
Compelling clinical evidence supporting efficacy: Patients implanted for 28 days regained voluntary control of hand movements, performing tasks like grasping a can. Follow-up tests confirmed high electrode stability, movement selectivity, motor function improvement, and over 90% compliance. Results published in Nature Scientific Reports and Journal of Neurotrauma.
Expanding Intellectual Property portfolio: First-mover in selective neurostimulation with seven patent families, trade secrets, and deep academic collaborations.
Strategic execution and commercialisation plan: Outsourced manufacturing to leading partners ensures scalable production and cost optimisation.
Far-reaching potential beyond prehension: Future applications include lower limb paralysis, post-stroke rehabilitation, micturition and incontinence treatment, and other neurological disorders.
Experienced leadership and strong Investor Backing: Highly skilled team with deep neurostimulation expertise. Supported by life science investors and European Union-backed projects.

World-first achievements in selective neurostimulation

Neurinnov, in collaboration with researchers at INRIA, has achieved a world-first breakthrough, enabling two patients with complete tetraplegia to temporarily regain hand movements solely through nerve stimulation. Unlike existing solutions, this innovation offers a new path for patients with severe functional impairments who would otherwise have no viable treatment options.

Using Neurinnov’s proprietary ASIC neural stimulation platform, the neurostimulation device allowed patients to perform essential daily tasks such as drinking from a straw and feeding themselves with a fork. This milestone marks the beginning of the platform’s vast potential to address major unmet medical needs.

Having successfully demonstrated proof of concept, Neurinnov is now advancing the device towards industrial-scale development. The platform’s technological leap enables the selective stimulation of any peripheral nerve, unlocking a wide range of future applications beyond spinal cord injury.

Strategic rationale for targeting hand function first

Hand function was selected as the initial clinical target for two key reasons:

Validation of the technology platform: Demonstrating the versatility of Neurinnov’s approach by addressing a market with significant unmet needs.
Faster time-to-market: The absence of existing solutions eliminates the need for placebo-controlled efficacy studies, streamlining regulatory approval.

The choice of prehension also stems from its complexity:

Mechanical complexity – The hand is one of the most intricate motor systems in the human body.
Neural command complexity – Coordinating multiple muscle groups requires highly sophisticated neural stimulation.
High sensory receptor density – The hand contains an exceptionally high concentration of sensory neurons, making precise and selective stimulation crucial.

By proving its effectiveness in such a challenging application, Neurinnov’s neurostimulation platform establishes a strong foundation for future indications and broader clinical adoption.

Target applications
of the ASIC neural stimulation platform

Solution can target any nerve

Neurinnov’s unique approach selectively activates targeted nerve fascicles, recruiting associated muscles by steering electrical currents exclusively through specific nerve areas. This sets it apart from conventional implantable techniques, which typically target entire nerves or even muscle tissue directly, methods that have known limitations.

Unlike conventional methods, which cannot achieve the same level of complexity, Neurinnov’s technology precisely directs current within specific nerve fascicles. This capability allows Neurinnov’s ASIC neural stimulation platform to target and activate any nerve in the body, a key factor in improving symptoms and restoring function in patients with neuromuscular, sensory-motor system, or neurological disorders.

Please contact us to learn more
about investment opportunities at Neurinnov

Current Investors

Advised by

Neurostimulation: seize a growing opportunity

Neurinnov: A PIONEER IN NEUROSTIMULATION WITH STRONG FOUNDATIONS